

References

I-260

1. Imjudo® (tremelimumab-actl) injection, for intravenous use [package insert]. AstraZeneca Pharmaceuticals LP. Wilmington, DE. Revised 11/2022.
2. Clinical Pharmacology™ Compendium. 2022. Tampa FL: Gold Standard, Inc. Tremelimumab.
3. Micromedex DrugDex Compendium®. 2022. Tremelimumab-actl.
4. Ghassan K, Chan S, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA. *J Clin Oncol.* 2022;40(4):379.
5. Johnson M, Cho B, Luft A, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study. *J Clin Oncol.* 2022;JCO2200975.